Want to see IN:BROOKS full AI Analyst Report?

Brooks Laboratories Limited (BROOKS) Price & Analysis

2 Followers

BROOKS Stock Chart & Stats

₹123.65

-₹3.80(-2.00%)

At close: Jan 09 4:00 PM EST

₹123.65

-₹3.80(-2.00%)

Day’s Range― - ―

52-Week Range₹36.50 - ₹165.95

Previous CloseN/A

Volume3.81K

Average Volume (3M)2.20K

Market Cap

₹2.24B

Enterprise Value₹1.98B

Total Cash (Recent Filing)₹18.03M

Total Debt (Recent Filing)₹78.33M

Price to Earnings (P/E)9.1

Beta1.73

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)3.97

Shares Outstanding29,457,249

10 Day Avg. Volume1,280

30 Day Avg. Volume2,199

Financial Highlights & Ratios

PEG Ratio-0.01

Price to Book (P/B)0.89

Price to Sales (P/S)1.27

P/FCF Ratio21.48

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetVery low leverage (debt-to-equity ~0.07) and a growing equity base give the company durable financial flexibility. Over the medium term this reduces default risk, preserves borrowing capacity for strategic investments or M&A, and cushions operating volatility.

Profitability TurnaroundA clear earnings recovery with a ~29% net margin and ~20% ROE implies the business can generate healthy returns when volumes and costs align. Sustained profitability supports reinvestment, debt servicing and long-term strategic initiatives if management maintains discipline.

Improving Cash GenerationOperating and free cash flow turned positive in FY2026 after prior outflows, indicating restoration of cash generation capacity. If sustained, this strengthens funding for capex, working capital and reduces reliance on external financing over the next several quarters.

Bears Say

Sharp Revenue DeclineA ~23% top-line drop materially endangers scale economics and questions demand sustainability. Persisting revenue contraction would erode margins, reduce pricing power and make the current profit levels harder to sustain without clear signs of market-share recovery or new revenue streams.

Weak Cash ConversionOperating cash flow covering under 50% of net income signals earnings are not fully converting to cash. This undermines the durability of reported profits, limits internal funding for growth or dividends, and raises the risk of needing external capital during stress periods.

Historical Margin VolatilityA history of losses and extreme margin swings indicates execution and structural risks in the business model. Such volatility increases uncertainty around repeatable profitability and heightens sensitivity to pricing, input costs, or product mix shifts over the medium term.

Brooks Laboratories Limited News

Brooks Laboratories Announces Strategic Merger of Joint Venture

Brooks Laboratories Limited ( ($IN:BROOKS) ) has shared an announcement. Brooks Laboratories Limited has announced a merger by...

9M ago

BROOKS FAQ

What was Brooks Laboratories Limited’s price range in the past 12 months?

Brooks Laboratories Limited lowest stock price was ₹36.50 and its highest was ₹165.95 in the past 12 months.

What is Brooks Laboratories Limited’s market cap?

Brooks Laboratories Limited’s market cap is ₹2.24B.

When is Brooks Laboratories Limited’s upcoming earnings report date?

Brooks Laboratories Limited’s upcoming earnings report date is Aug 07, 2026 which is in 33 days.

How were Brooks Laboratories Limited’s earnings last quarter?

Brooks Laboratories Limited released its earnings results on May 29, 2026. The company reported ₹0.52 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.52.

Is Brooks Laboratories Limited overvalued?

According to Wall Street analysts Brooks Laboratories Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Brooks Laboratories Limited pay dividends?

Brooks Laboratories Limited does not currently pay dividends.

What is Brooks Laboratories Limited’s EPS estimate?

Brooks Laboratories Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Brooks Laboratories Limited have?

Brooks Laboratories Limited has 29,457,249 shares outstanding.

What happened to Brooks Laboratories Limited’s price movement after its last earnings report?

Brooks Laboratories Limited reported an EPS of ₹0.52 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 4.998%.

Which hedge fund is a major shareholder of Brooks Laboratories Limited?

Currently, no hedge funds are holding shares in IN:BROOKS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Brooks Laboratories Limited

Brooks Laboratories Limited is a pharmaceutical enterprise engaged in the contractual manufacturing and distribution of medicinal products. The company serves both the Indian domestic market and international clients. Its comprehensive product portfolio includes carbapenem medications, various tablets, dry syrups, both liquid and powdered injectable solutions, and specialized eye and ear drops. Brooks Laboratories Limited was established in 2002 and is headquartered in Mumbai, India.